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1. INTRODUCTION {#jcb28378-sec-0010}
===============

Cancer is a major public health burden worldwide and has been the leading cause of death in China since 2010.[1](#jcb28378-bib-0001){ref-type="ref"} Aging and unhealthy lifestyle (e.g. smoking, alcohol consumption, physical inactivity, and high fat, sugar and calorie diets) may contribute to the global burden of cancer.[2](#jcb28378-bib-0002){ref-type="ref"}, [3](#jcb28378-bib-0003){ref-type="ref"}, [4](#jcb28378-bib-0004){ref-type="ref"} However, the carcinogenic effect is very complicated and remains unknown. Some studies reported that obesity, overweight, and type 2 diabetes may contribute to an individual's cancer susceptibility.[5](#jcb28378-bib-0005){ref-type="ref"}, [6](#jcb28378-bib-0006){ref-type="ref"}, [7](#jcb28378-bib-0007){ref-type="ref"}

Leptin (LEP), a hormone of energy expenditure, may contribute to control energy expenditure and balance by suppressing hunger. LEP, a 16 kDa glycol‐protein, is predominantly made (\>95%) by fat cells.[8](#jcb28378-bib-0008){ref-type="ref"} LEP interacts with LEP‐receptor in the hypothalamus. A number of studies focused on the role of LEP in energy homeostasis and obesity. In addition, some investigations have demonstrated that LEP is associated with insulin signaling, inflammatory, and immune response.[9](#jcb28378-bib-0009){ref-type="ref"}, [10](#jcb28378-bib-0010){ref-type="ref"} Recently, several researchers reported that serum LEP levels might influence the development and progression of cancer.[11](#jcb28378-bib-0011){ref-type="ref"}, [12](#jcb28378-bib-0012){ref-type="ref"}

It is found that the *LEP* rs2167270 G \> A (G19A) locus is correlated with LEP levels and may also give a fascinating insight into the potential correlations with the development of cancer.[13](#jcb28378-bib-0013){ref-type="ref"}, [14](#jcb28378-bib-0014){ref-type="ref"} In a previous pooled study, it was found that individuals carrying a *LEP* 19A allele might have a lower tendency for cancer risk.[15](#jcb28378-bib-0015){ref-type="ref"} However, most of the eligible studies focused on Caucasians. The potential relationship of this single‐nucleotide polymorphism (SNP) with cancer risk for Asians is unclear. Of late, several case‐control studies investigating the association between *LEP* G19A polymorphism and cancer risk have been performed in Asians with relatively large samples.[16](#jcb28378-bib-0016){ref-type="ref"}, [17](#jcb28378-bib-0017){ref-type="ref"} Thus, it may be meaningful to obtain data from additional studies to get a more meaningful assessment of genetic effects.

In this study, to acquire an understanding of the relationship between LEP polymorphism and risk of cancer, we first studied *LEP* G19A polymorphism with the susceptibility of developing esophagogastric junction adenocarcinoma (EGJA). And then, we performed a meta‐analysis to estimate the relationship of this polymorphism with overall cancer risk.

2. MATERIALS AND METHODS {#jcb28378-sec-0020}
========================

2.1. Case‐control study {#jcb28378-sec-0030}
-----------------------

A total of 1063 unrelated EGJA cases were diagnosed and selected at Fujian Medical University Union Hospital, Fujian Medical University Cancer Hospital and Affiliated People's Hospital of Jiangsu University. In addition, 1677 noncancer subjects were included in a control group. Both groups belonged to the Chinese Han populations from eastern China. The patients included 759 males and 304 females; the average age was 64.19 ± 8.63 years. Of them, 625 patients had lymph node metastases. There were 305 stage I/II and 758 stage III/IV EGJA patients included in the case group.[17](#jcb28378-bib-0017){ref-type="ref"} The disease stage was assessed according to AJCC criteria (version 7.0). The control group was composed of 1194 males and 483 females with the mean age of 63.91 ± 10.22 years. Information regarding smoking and drinking has been described in our previous study.[17](#jcb28378-bib-0017){ref-type="ref"}, [18](#jcb28378-bib-0018){ref-type="ref"} Each participant signed a written informed consent. This study was approved by the review boards of the Jiangsu University as well as the Fujian Medical University. The genomic DNA was carefully extracted from peripheral venous blood of participants by using DNA Kit (Promega, Madison, Wisconsin). The *LEP* G19A polymorphism was detected by SNPscan genotyping assay (Genesky Biotechnologies Inc., Shanghai, China) according to conditions described by Chen et al.[17](#jcb28378-bib-0017){ref-type="ref"}

2.2. Meta‐analysis {#jcb28378-sec-0040}
------------------

We performed an extensive literature search in PubMed and EMBASE databases, covering all medical publications until 24 August 2018, with the following key words: LEP gene (e.g.: 'LEP' or 'leptin'), cancer (e.g. 'carcinoma,' 'cancer,' 'maligancy' or 'neoplasms'), and polymorphism (e.g.: 'polymorphism,' 'SNP' or 'variation'). In addition, we also carried out a manual search of the listed references of the included publications and related reviews.

The criteria of literature selection were as follows: (a) investigation designed as a case--control study; (b) focusing on the association of *LEP* G19A polymorphism with risk of cancer; (c) genotypes data listing in the publications. The major exclusion criteria of studies were as follows: (a) reviews; (b) duplicated reports; (c) not case‐control study designs; (c) lack of data for genotype frequencies.

Two authors (J. Yang and Z. Zhong) extracted data from the included publications independently. The following information was collected: (a) first author; (b) publication year; (c) number of cases and controls; (d) country; (e) ethnicity; (f) source of controls; (g) cancer type; (h) genotyping method; and (I) genotype frequency. Ethnicities were defined as mixed, Asians, and Caucasians. For the source of controls, the publications were categorized as hospital‐based and population‐based studies.

In this study, we analyzed Hardy‐Weinberg equilibrium (HWE) using a goodness‐of‐fit test using an online software (<https://ihg.gsf.de/cgi-bin/hw/hwa1.pl>). The strength of the correlation between *LEP* G19A locus and cancer risk was determined by calculating crude odds ratios (ORs) with their 95% confidence intervals (95% CIs). The following four models were calculated: homozygote comparison (AA vs GG), dominant model (AA/GA vs GG), recessive model (AA vs GG/GA), and allele model (A vs G). If *I* ^*2*^ \> 50% or *P* \< 0.1, it suggested that there was significant heterogeneity. Considering the heterogeneity among the included studies, a different model was used to pool the data. When no significant heterogeneity was identified, the Mantel‐Haenszel method (fixed effects model) was used[19](#jcb28378-bib-0019){ref-type="ref"}; otherwise, the Der Simonian and Laird method (random model) was utilized.[20](#jcb28378-bib-0020){ref-type="ref"}, [21](#jcb28378-bib-0021){ref-type="ref"} Sensitivity analysis was also carried out, which deletes an individual investigation and, in turn, recalculates the remainders. The source of heterogeneity among variables (e.g. cancer type, ethnicity) was explored by subgroup analysis. Begg's funnel plot and Egger's regression method were harnessed to examine the publication bias among the included studies. And *P* \< 0.1 was defined as representative of significant bias. The Newcastle‐Ottawa Quality Assessment Scale was used to assess the quality of the enrolled literatures. If scores ≥ 6 stars, the publication was considered as related high‐quality. In this study, all *P* values for statistics were calculated with two‐sided. STATA 12.0 software (Stata Corp, College Station, Texas) was used to analyze the data.

3. RESULTS {#jcb28378-sec-0050}
==========

3.1. Case‐control study {#jcb28378-sec-0060}
-----------------------

A total of 2740 participants (involving 1063 EGJA patients and 1677 cancer‐free controls) were included in this case‐control study. Table [1](#jcb28378-tbl-0001){ref-type="table"} summarizes the primary information and our data for *LEP* G19A polymorphism.

###### 

Primary information for *LEP* G19A polymorphism

  Genotyped SNPs   MAF[^a^](#jcb28378-tbl1-note-0002){ref-type="fn"} for Chinese in database   MAF in our controls (*N* = 1677)   *P* value for HWE[^b^](#jcb28378-tbl1-note-0003){ref-type="fn"} test in our controls   Genotyping method   Genotyping value, %
  ---------------- --------------------------------------------------------------------------- ---------------------------------- -------------------------------------------------------------------------------------- ------------------- ---------------------
  *LEP* G19A       0.175                                                                       0.224                              0.129                                                                                  SNPscan             99.09

Abbreviation: SNP, single‐nucleotide polymorphism.

MAF: minor allele frequency.

HWE: Hardy‐Weinberg equilibrium.

John Wiley & Sons, Ltd.

Table [2](#jcb28378-tbl-0002){ref-type="table"} shows the genotype distributions of *LEP* G19A polymorphism. In the analysis of *LEP* G19A polymorphism, differences in the distribution of *LEP* G19A genotypes between EGJA patients and controls were found \[GA vs GG: crude OR = 0.79, 95% CI = 0.67--0.93, *P* = 0.006; AA vs GG: crude OR = 0.57, 95% CI = 0.37--0.88, *P* = 0.012, GA/AA vs GG: crude OR = 0.79, 95% CI = 0.67--0.93, *P* = 0.004 and AA vs GG/GA: crude OR = 0.63, 95% CI = 0.41--0.97, *P* = 0.038\]. The results of multivariate linear regression analysis also showed that *LEP* G19A polymorphism was correlated with a decreased risk of EGJA (GA vs GG: adjusted OR = 0.79, 95% CI = 0.67--0.93, *P* = 0.005; AA vs GG: adjusted OR = 0.58, 95% CI = 0.37--0.90, *P* = 0.015, GA/AA vs GG: adjusted OR = 0.79, 95% CI = 0.67--0.93, *P* = 0.004 and AA vs GG/GA: adjusted OR = 0.64, 95% CI = 0.41--0.99, *P* = 0.046).

###### 

Logistic regression analyses of association between *LEP* G19A polymorphism and risk of EGJA

                           Cases (*n* = 1063)   Controls (*n* = 1677)                                                                          
  ------------------------ -------------------- ----------------------- ------ ------- --------------------- ----------- --------------------- -----------
  *LEP* rs2167270 G \> A                                                                                                                       
  GG                       678                  65.13                   998    59.62   1.00                              1.00                  
  GA                       334                  32.08                   603    36.02   **0.79(0.67‐0.93)**   **0.006**   **0.79(0.67‐0.93)**   **0.005**
  AA                       29                   2.79                    73     4.36    **0.57(0.37‐0.88)**   **0.012**   **0.58(0.37‐0.90)**   **0.015**
  GA + AA                  363                  34.87                   676    40.38   **0.79(0.67‐0.93)**   **0.004**   **0.79(0.67‐0.93)**   **0.004**
  GG + GA                  1012                 97.21                   1601   95.64   1.00                              1.00                  
  AA                       29                   2.79                    73     4.36    **0.63(0.41‐0.97)**   **0.038**   **0.64(0.41‐0.99)**   **0.046**
  A allele                 392                  18.83                   749    22.37                                                           

Abbreviation: EGJA, esophagogastric junction adenocarcinoma.

Bold values are statistically significant (*P* \< 0.05).

Adjusted for age, sex, smoking status, alcohol use and BMI status.

John Wiley & Sons, Ltd.

3.2. Meta‐analysis {#jcb28378-sec-0070}
------------------

We have summarized the meta‐analysis process in Figure [1](#jcb28378-fig-0001){ref-type="fig"}. Finally, a total of 13 case‐control studies with 8059 cases and 11 930 controls were included in our analysis (Table [3](#jcb28378-tbl-0003){ref-type="table"}). There were four case‐control studies and our investigation, conducted in Asian population,[16](#jcb28378-bib-0016){ref-type="ref"}, [17](#jcb28378-bib-0017){ref-type="ref"}, [22](#jcb28378-bib-0022){ref-type="ref"}, [23](#jcb28378-bib-0023){ref-type="ref"} six case‐control studies focused on Caucasian population,[24](#jcb28378-bib-0024){ref-type="ref"}, [25](#jcb28378-bib-0025){ref-type="ref"}, [26](#jcb28378-bib-0026){ref-type="ref"}, [27](#jcb28378-bib-0027){ref-type="ref"}, [28](#jcb28378-bib-0028){ref-type="ref"}, [29](#jcb28378-bib-0029){ref-type="ref"} and two case‐control studies performed in mixed population.[30](#jcb28378-bib-0030){ref-type="ref"}, [31](#jcb28378-bib-0031){ref-type="ref"} Tables [3](#jcb28378-tbl-0003){ref-type="table"} and [4](#jcb28378-tbl-0004){ref-type="table"} show the characteristics and genotyping data of the included studies, respectively. Table [5](#jcb28378-tbl-0005){ref-type="table"} demonstrate the process of quality assessment in this meta‐analysis.

![Flow diagram of the meta--analysis](JCB-120-10998-g001){#jcb28378-fig-0001}

###### 

Characteristics of the studies in meta‐analysis

  References                                                    Publication year   Country     Ethnicity    Cancer type                               Sample size (case/control)   Source of control   Genotype method
  ------------------------------------------------------------- ------------------ ----------- ------------ ----------------------------------------- ---------------------------- ------------------- -----------------
  Skibola et al[24](#jcb28378-bib-0024){ref-type="ref"}         2004               USA         Caucasians   Non‐Hodgkin lymphoma                      376/805                      PB                  TaqMan
  Willett et al[25](#jcb28378-bib-0025){ref-type="ref"}         2005               UK          Caucasians   Non‐Hodgkin lymphoma                      699/914                      PB                  TaqMan
  Doecke et al[26](#jcb28378-bib-0026){ref-type="ref"}          2008               Australia   Caucasians   Esophageal cancer                         774/1352                     PB                  Sequenom iPLEX
  Slattery et al[30](#jcb28378-bib-0030){ref-type="ref"}        2008               USA         Mixed        Colorectal cancer                         1565/1965                    Mixed               TaqMan
  Tsilidis et al[31](#jcb28378-bib-0031){ref-type="ref"}        2009               USA         Mixed        Colorectal cancer                         208/381                      PB                  TaqMan
  Wang et al[27](#jcb28378-bib-0027){ref-type="ref"}            2009               USA         Caucasians   Prostate cancer                           258/258                      PB                  TaqMan
  Moore et al[28](#jcb28378-bib-0028){ref-type="ref"}           2009               Finland     Caucasians   Prostate cancer                           1053/1053                    PB                  TaqMan
  Partida‐Perez et al[29](#jcb28378-bib-0029){ref-type="ref"}   2010               Mexico      Caucasians   Colorectal cancer                         68/102                       HB                  PCR‐RFLP
  Zhang et al[22](#jcb28378-bib-0022){ref-type="ref"}           2012               China       Asians       Non‐Hodgkin lymphoma                      514/557                      HB                  TaqMan
  Kim et al[23](#jcb28378-bib-0023){ref-type="ref"}             2012               Korea       Asians       Breast cancer                             390/447                      HB                  MassARAY
  Qiu et al[16](#jcb28378-bib-0016){ref-type="ref"}             2017               China       Asians       Esophageal cancer                         507/1496                     HB                  SNPscan
  Zhang et al[17](#jcb28378-bib-0017){ref-type="ref"}           2018               China       Asians       Hepatocellular carcinoma                  584/923                      HB                  SNPscan
  Our study                                                     2018               China       Asians       Esophagogastric junction adenocarcinoma   1063/1677                    HB                  SNPscan

Abbreviations: HB, hospital‐based;

PB, population‐based.

John Wiley & Sons, Ltd.

###### 

Distribution of *LEP* G19A polymorphism genotype and allele

  References                                                    Publication year   Case AA   Case AG   Case GG   Control AA   Control AG   Control GG   Case A   Case G   Hardy‐Weinberg equilibrium
  ------------------------------------------------------------- ------------------ --------- --------- --------- ------------ ------------ ------------ -------- -------- ----------------------------
  Skibola et al[24](#jcb28378-bib-0024){ref-type="ref"}         2004               36        169       168       119          335          351          241      505      No
  Willett et al[25](#jcb28378-bib-0025){ref-type="ref"}         2005               79        276       235       122          357          275          434      746      Yes
  Doecke et al[26](#jcb28378-bib-0026){ref-type="ref"}          2008               34        130       94        176          622          541          198      318      Yes
  Slattery et al[30](#jcb28378-bib-0030){ref-type="ref"}        2008               190       766       611       304          867          794          1146     1988     No
  Tsilidis et al[31](#jcb28378-bib-0031){ref-type="ref"}        2009               33        91        80        61           170          131          157      251      Yes
  Wang et al[27](#jcb28378-bib-0027){ref-type="ref"}            2009               39        122       92        38           119          100          200      306      Yes
  Moore et al[28](#jcb28378-bib-0028){ref-type="ref"}           2009               113       404       428       107          387          346          630      1260     Yes
  Partida‐Perez et al[29](#jcb28378-bib-0029){ref-type="ref"}   2010               7         44        17        25           53           24           58       78       Yes
  Zhang et al[22](#jcb28378-bib-0022){ref-type="ref"}           2012               26        166       322       29           190          338          218      810      Yes
  Kim et al[23](#jcb28378-bib-0023){ref-type="ref"}             2012               12        110       269       18           147          284          134      648      Yes
  Qiu et al[16](#jcb28378-bib-0016){ref-type="ref"}             2017               19        165       318       67           528          894          203      801      Yes
  Zhang et al[17](#jcb28378-bib-0017){ref-type="ref"}           2018               34        198       343       36           321          564          266      884      Yes
  Our study                                                     2018               29        334       678       73           603          998          392      1690     Yes

John Wiley & Sons, Ltd.

###### 

Quality assessment of the meta‐analysis

                                                                       Selection       Exposure                                 
  ------------------------------------------------------------- ------ ----------- --- ---------- ----- ----- ----- ----- ----- ---
  Skibola et al[24](#jcb28378-bib-0024){ref-type="ref"}         2004   ★           ★   ★          ★     ★★    ★     ...   ...   7
  Willett et al[25](#jcb28378-bib-0025){ref-type="ref"}         2005   ★           ★   ★          ★     ★★    ★     ...   ...   7
  Doecke et al[26](#jcb28378-bib-0026){ref-type="ref"}          2008   ★           ★   ★          ★     ...   ...   ...   ...   4
  Slattery et al[30](#jcb28378-bib-0030){ref-type="ref"}        2008   ★           ★   ...        ★     ★★    ★     ...   ...   6
  Tsilidis et al[31](#jcb28378-bib-0031){ref-type="ref"}        2009   ★           ★   ★          ★     ★★    ★     ...   ...   7
  Wang et al[27](#jcb28378-bib-0027){ref-type="ref"}            2009   ★           ★   ★          ★     ★★    ★     ...   ...   7
  Moore et al[28](#jcb28378-bib-0028){ref-type="ref"}           2009   ★           ★   ★          ...   ...   ...   ...   ...   3
  Partida‐Perez et al[29](#jcb28378-bib-0029){ref-type="ref"}   2010   ★           ★   ...        ★     ...   ★     ...   ...   4
  Zhang et al[22](#jcb28378-bib-0022){ref-type="ref"}           2012   ★           ★   ...        ★     ★★    ★     ...   ...   6
  Kim et al[23](#jcb28378-bib-0023){ref-type="ref"}             2012   ★           ★   ...        ★     ★★    ★     ...   ...   6
  Qiu et al[16](#jcb28378-bib-0016){ref-type="ref"}             2017   ★           ★   ...        ★     ★★    ★     ...   ...   6
  Zhang et al[17](#jcb28378-bib-0017){ref-type="ref"}           2018   ★           ★   ...        ★     ★★    ★     ...   ...   6
  Our study                                                     2018   ★           ★   ...        ★     ★★    ★     ...   ...   6

^★^means meet the standard

John Wiley & Sons, Ltd.

As demonstrated in Table [6](#jcb28378-tbl-0006){ref-type="table"}, we identified a significant association of the G19A polymorphism in the *LEP* 5′‐UTR region with a decreased risk of overall cancer in four genetic models (A vs G: OR = 0.92, 95% CI = 0.88--0.97, *P* = 0.001; AA vs GG: OR = 0.83, 95% CI = 0.74--0.93, *P* = 0.001, GA/AA vs GG: OR = 0.93, 95% CI = 0.88--0.99, *P* = 0.023 and AA vs GG/GA: OR = 0.83, 95% CI = 0.74--0.92, *P* \< 0.001, Figure [2](#jcb28378-fig-0002){ref-type="fig"}). In this study, two studies were inconsistent with HWE.[24](#jcb28378-bib-0024){ref-type="ref"}, [30](#jcb28378-bib-0030){ref-type="ref"} When we excluded these studies, we also found that *LEP* G19A polymorphism decreased the risk of overall cancer (A vs G: OR = 0.92, 95% CI = 0.87--0.97, *P* = 0.002; AA vs GG: OR = 0.87, 95% CI = 0.75--0.99, *P* = 0.041 and GA/AA vs GG: OR = 0.90, 95% CI = 0.83--0.96, *P* = 0.003).

###### 

Results of the meta‐analysis from different comparative genetic models

                        A vs G                AA vs GG    AA + AG vs GG   AA vs AG + GG                                                                                                                                                   
  ---------------- ---- --------------------- ----------- --------------- --------------- --------------------- ----------- ------- ------- --------------------- ----------- ------- ------- --------------------- ------------- ------- -------
  Total            13   **0.92(0.88‐0.97)**   **0.001**   26.1%           0.180           **0.83(0.74‐0.93)**   **0.001**   25.9%   0.183   **0.93(0.88‐0.99)**   **0.023**   26.8%   0.174   **0.83(0.74‐0.92)**   **\<0.001**   32.3%   0.124
  HWE^a^           11   **0.92(0.87‐0.97)**   **0.002**   33.6            0.130           **0.87(0.75‐0.99)**   **0.041**   28.7    0.172   **0.90(0.83‐0.96)**   **0.003**   14.9%   0.302   0.89(0.78‐1.01)       0.080         24.7%   0.209
  Ethnicity                                                                                                                                                                                                                               
  Caucasians       6    **0.92(0.85‐1.00)**   **0.040**   20.3%           0.281           **0.82(0.70‐0.97)**   **0.022**   27.7%   0.227   0.94(0.84‐1.04)       0.237       4.6%    0.387   **0.83(0.71‐0.97)**   **0.017**     38.3%   0.151
  Mixed            2    0.95(0.87‐1.05)       0.317       0.0%            0.791           **0.82(0.68‐1.00)**   **0.048**   0.0%    0.756   1.04(0.91‐1.18)       0.588       0.0%    0.330   **0.78(0.65‐0.93)**   **0.007**     0.0%    0.362
  Asians           5    0.90(0.80‐1.02)       0.105       55.0%           0.064           0.87(0.61‐1.25)       0.452       55.8%   0.060   **0.87(0.79‐0.96)**   **0.005**   29.7%   0.223   0.91(0.65‐1.27)       0.571         48.8%   0.099
  Cancer type                                                                                                                                                                                                                             
  NHL              3    **0.89(0.80‐0.99)**   **0.025**   0.0%            0.819           **0.74(0.59‐0.94)**   **0.012**   0.0%    0.521   0.91(0.79‐1.04)       0.161       0.0%    0.875   **0.76(0.61‐0.94)**   **0.013**     0.0%    0.372
  EC               2    0.98(0.80‐1.20)       0.834       57.7%           0.124           0.97(0.70‐1.35)       0.849       0.0%    0.335   1.00(0.74‐1.35)       0.999       67.1%   0.081   0.94(0.68‐1.28)       0.681         0.0%    0.581
  CRC              3    0.94(0.86‐1.03)       0.205       0.0%            0.478           **0.80(0.66‐0.97)**   **0.023**   0.0%    0.381   1.03(0.91‐1.17)       0.620       0.0%    0.593   **0.75(0.63‐0.90)**   **0.002**     45.6%   0.159
  PC               2    0.93(0.83‐1.06)       0.275       29.7%           0.233           0.91(0.70‐1.18)       0.485       0.0%    0.389   0.90(0.76‐1.06)       0.204       43.9%   0.182   0.96(0.75‐1.22)       0.740         0.0%    0.672
  Others           3    0.90(0.72‐1.12)       0.341       76.9%           0.013           0.87(0.45‐1.68)       0.679       77.4%   0.012   0.87(0.71‐1.07)       0.194       63.5%   0.064   0.91(0.50‐1.67)       0.756         73.9%   0.022
  Quality scores                                                                                                                                                                                                                          
  ≥6.0             10   **0.92(0.87‐0.97)**   **0.001**   25.8%           0.206           **0.82(0.72‐0.93)**   **0.001**   27.3%   0.192   **0.93(0.87‐0.99)**   **0.033**   28.0%   0.187   **0.81(0.72‐0.91)**   **\<0.001**   28.8%   0.180
  \<6.0            3    0.94(0.84‐1.05)       0.280       49.2%           0.139           0.89(0.70‐1.13)       0.327       41.9%   0.179   0.94(0.81‐1.09)       0.429       26.8%   0.174   0.83(0.56‐1.23)       0.359         55.2%   0.107

Abbreviatons: CRC, colorectal cancer; EC, esophageal cancer; HWE, Hardy‐Weinberg equilibrium; NHL, non‐Hodgkin lymphoma; PC, prostate cancer.

Bold values are statistically significant (*P* \< 0.05).

John Wiley & Sons, Ltd.

![Meta‐analysis of the relationship between *LEP* G19A polymorphism and overall cancer risk (A vs G, fixed--effects model)](JCB-120-10998-g002){#jcb28378-fig-0002}

When an analysis stratified by cancer type was conducted, we found that individuals carrying *LEP* 19 A allele might have a lower susceptibility of NHL in three models (A vs G: OR = 0.89, 95% CI = 0.80--0.99, *P* = 0.025; AA vs GG: OR = 0.74, 95% CI = 0.59--0.94, *P* = 0.012 and AA vs GA/GG: OR = 0.76, 95% CI = 0.61--0.94, *P* = 0.013). In addition, we also found that the G19A polymorphism in *LEP* gene was correlated with a decreased susceptibility of CRC in homozygote comparison (OR = 0.80, 95% CI: 0.66‐0.97, *P* = 0.023) and recessive model (OR = 0.75, 95% CI: 0.63‐0.90, *P* = 0.002).

In an analysis stratified by ethnicities, significant associations were found also in Asians (GA/AA vs GG: OR = 0.87, 95% CI = 0.79--0.96, *P* = 0.005), Caucasians for three models (A vs G: OR = 0.92, 95% CI = 0.85--1.00, *P* = 0.040; AA vs GG: OR = 0.82, 95% CI = 0.70--0.97, *P* = 0.048 and AA vs GG/GA: OR = 0.83, 95% CI = 0.71--0.97, *P* = 0.017), and mixed population (AA vs GG: OR = 0.82, 95% CI = 0.68--1.00, *P* = 0.048 and AA vs GG/GA: OR = 0.78, 95% CI = 0.65--0.93, *P* = 0.007).

We checked publication bias by using Begg's funnel plot and Egger's test. The statistical results showed that there was no significant bias in this meta‐analysis (A vs G: Begg's test *P* = 1.00, Egger's test *P* = 0.825; AA vs GG: Begg's test *P* = 0.951, Egger's test *P* = 0.975; GA/AA vs GG: Begg's test *P* = 0.428, Egger's test *P* = 0.981; AA vs GA/GG: Begg's test *P* = 0.760, Egger's test *P* = 0.847; Figure [3](#jcb28378-fig-0003){ref-type="fig"}). One‐way sensitivity analysis was harnessed to confirm the stability of our findings. And we found that the corresponding results were not materially altered (Figure [4](#jcb28378-fig-0004){ref-type="fig"}).

![Begg's funnel plot of meta--analysis (A vs G, fixed--effects model)](JCB-120-10998-g003){#jcb28378-fig-0003}

![Sensitivity analysis of the influence of A vs G comparison (fixed--effects model)](JCB-120-10998-g004){#jcb28378-fig-0004}

We assessed the quality score of the eligible studies by using the Newcastle‐Ottawa Quality Assessment Scale.[32](#jcb28378-bib-0032){ref-type="ref"} The results are shown in Table [5](#jcb28378-tbl-0005){ref-type="table"}. When the related low‐quality studies (\<6.0) were excluded, the findings were not substantially changed (Table [6](#jcb28378-tbl-0006){ref-type="table"}).

4. DISCUSSION {#jcb28378-sec-0080}
=============

In this case‐control study, we found that *LEP* G19A polymorphism decreased the risk of EGJA. To the best of our knowledge, the first pooled‐analysis that carried out an extensive evaluation of the G19A polymorphism in the *LEP* 5′‐UTR region with the risk of overall cancer was conducted in 2014.[15](#jcb28378-bib-0015){ref-type="ref"} In our meta‐analysis, 13 publications involving 8059 cases and 11 930 controls were included. Compared with the previous study, more new studies performed in Asian population were recruited.[16](#jcb28378-bib-0016){ref-type="ref"}, [17](#jcb28378-bib-0017){ref-type="ref"} Although some studies suggested that *LEP* G19A polymorphism could increase the risk of cancer,[17](#jcb28378-bib-0017){ref-type="ref"} the pooled ORs of our study confirmed that G19A polymorphism in *the LEP* gene was correlated with a decreased risk of overall cancer. It is worth noting that this potential association was also observed in Caucasians, Asians, mixed populations, and NHL and CRC subgroups.

In the past few decades, some case‐control studies have been designed to explore the potential relationship between G19A polymorphism in the *LEP* gene and the risk of cancer.[16](#jcb28378-bib-0016){ref-type="ref"}, [17](#jcb28378-bib-0017){ref-type="ref"}, [22](#jcb28378-bib-0022){ref-type="ref"}, [23](#jcb28378-bib-0023){ref-type="ref"}, [24](#jcb28378-bib-0024){ref-type="ref"}, [25](#jcb28378-bib-0025){ref-type="ref"}, [26](#jcb28378-bib-0026){ref-type="ref"}, [27](#jcb28378-bib-0027){ref-type="ref"}, [28](#jcb28378-bib-0028){ref-type="ref"}, [29](#jcb28378-bib-0029){ref-type="ref"}, [30](#jcb28378-bib-0030){ref-type="ref"}, [31](#jcb28378-bib-0031){ref-type="ref"} Skibola et al[24](#jcb28378-bib-0024){ref-type="ref"} found that *LEP* G19A polymorphism decreased the risk of NHL in Caucasians. Another study also identified similar findings regarding CRC in mixed populations.[30](#jcb28378-bib-0030){ref-type="ref"} A previous meta‐analysis indicated that a tendency to decrease risk was noted between *LEP* G19A polymorphism and cancer.[15](#jcb28378-bib-0015){ref-type="ref"} However, for Asian population, only two case‐control studies with small sample sizes were included in this pooled analysis.[22](#jcb28378-bib-0022){ref-type="ref"}, [23](#jcb28378-bib-0023){ref-type="ref"} The association of *LEP* G19A polymorphism with cancer risk in Asians was unclear. Recently, several studies investigated the relationship between *LEP* G19A polymorphism and cancer risk in Asians.[16](#jcb28378-bib-0016){ref-type="ref"}, [17](#jcb28378-bib-0017){ref-type="ref"} And they found no association between this SNP and cancer risk. Recently, Zhang et al[17](#jcb28378-bib-0017){ref-type="ref"} reported that *LEP* G19A variants might increase the risk of HCC. The observed results were more controversial. In the current study, we conducted a case‐control study to identify the correlation between *LEP* G19A variants and the development of EGJA. We first found that *LEP* G19A polymorphism decreased the risk of EGJA in Asians. To estimate the relationship of *LEP* G19A polymorphism with cancer risk more extensively, we conducted an updated meta‐analysis. It was found that *LEP* G19A polymorphism may have a lower risk of overall cancer. *LEP* G19A polymorphism, a SNP in the 5′‐ untranslated region, could not be translated into amino acid peptides. However, this SNP may influence the RNA translation, stability, and transcription, and then alter the expression of LEP protein. A recent study indicated that *LEP* 19A allele is correlated with lower levels of LEP.[14](#jcb28378-bib-0014){ref-type="ref"} A meta‐analysis found that the decreased serum LEP levels were a protective factor to breast cancer risk.[11](#jcb28378-bib-0011){ref-type="ref"} It is conceivable that the reduced levels of serum LEP associated with *LEP* 19A allele may attenuate the risk of cancer. In this meta‐analysis, we confirmed this phenomenon. Furthermore, we identified a significant association in Caucasians and Asians for the first time.

The results of the heterogeneity analysis are shown in Table [6](#jcb28378-tbl-0006){ref-type="table"}. We found that there was no evident heterogeneity across studies. Publication bias was evaluated by Begg's funnel plots and Egger's linear regression test. The results showed that no significant bias was observed. In this meta‐analysis, we assessed quality of the included studies. We found that the related low‐quality studies did not influence the findings of overall evaluation. These findings indicated that our conclusions were credible and stable.

Some limitations of the present pooled‐analysis should be acknowledged, even though it was powered by involving the latest literatures as well as our case‐control study. First, when the data were extracted and pooled, it was found that significantly heterogeneities existed among certain subgroups. Thus, these observed results should be explained with caution in these subgroups. Second, for the lack of critical data (eg such as age, sex, BMI, and environmental factors), gene‐environment interaction could not be carried out. Third, in this study, only *LEP* G19A polymorphism was studied; the interaction of gene‐gene was not evaluated. Fourth, in this study, a functional study focusing on the *LEP* G19A polymorphism was not conducted. Finally, because the eligible studies were limited, our analysis may be underpowered in some subgroups.

In conclusion, it is highlighted that the G19A polymorphism in the *LEP* 5′‐UTR region is associated with a decreased risk of EGJA. In addition, the subsequent meta‐analysis also indicates that this SNP decreases the risk of overall cancer. To confirm or refute our findings, large scale case‐control studies are needed.
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